Dr Nancy E. Lane M.D., Distinguished Professor of Medicine and Rheumatology at the University of California at Davis, School of Medicine and U. C. Davis Health, has been awarded the 2021 International Osteoporosis Foundation (IOF) Committee of Scientific Advisors Medal of Achievement.

Presented today at the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (Virtual WCO-IOF-ESCEO 2021), the CSA IOF Medal of Achievement is awarded in honour of an individual researcher who has significantly advanced the field of osteoporosis through original and outstanding scientific contributions. The award underlines important aspects of IOF’s mission – to increase understanding and awareness of osteoporosis and to promote medical innovation and improved care.

Professor Cyrus Cooper, President of IOF, stated: “We are greatly honoured to present this prestigious award to Professor Nancy Lane. She is internationally renowned for her original and ground-breaking contributions to research  in the epidemiology and genetic composition of therapies for musculoskeletal disorders, including osteoporosis, osteoarthritis and inflammatory bone diseases.  IOF is privileged to count Professor Lane as a member of its Committee of Scientific Advisors.”

Dr.  Lane is a Distinguished Professor of Medicine and Rheumatology at the University of California at Davis, School of Medicine and U. C. Davis Health.  Dr. Lane was the inaugural Director for the Center for Musculoskeletal Health and the recipient of the Endowed Chair for Aging Research and Education for 16 years (2005 to 2020).  She has spent 35 years studying musculoskeletal Diseases of Aging, especially osteoporosis and osteoarthritis and has authored over 400 peer reviewed articles and trained many clinical and translational investigators to perform research in musculoskeletal diseases of aging.  Dr. Lane performed the initial proof of concept studies to determine that hPTH (1-34) was an effective and safe treatment to revert glucocorticoid induced osteoporosis, the NGF inhibitor Tenazumab for osteoarthritis pain, and has been a leader in the understanding and treatment of the bone diseases associated with inflammation. Dr Lane has been an elected volunteer to the Board of Scientific Advisors for the IOF and Board of the American Society of Bone and Mineral Research and the Osteoarthritis and Cartilage Society.    


About the World Congress on Osteoporosis, Osteoarthritis & Musculoskeletal Diseases (WCO-IOF-ESCEO)
Held jointly by IOF and ESCEO, the WCO-IOF-ESCEO annual congress is the world’s largest forum for the presentation of clinical research and new advances in the prevention and management of musculoskeletal disorders, including sarcopenia and frailty. WCO-IOF-ESCEO 2021 will be held as a virtual congress from August 26 to 28, 2021, with access on demand for registrants up to three months following the congress. For complete information visit  #OsteoCongress

About IOF
The International Osteoporosis Foundation (IOF) is the world's largest nongovernmental organization dedicated to the prevention, diagnosis and treatment of osteoporosis and related musculoskeletal diseases. IOF members, including committees of scientific researchers as well as 268 patient, medical and research societies, work together to make fracture prevention and healthy mobility a worldwide heath care priority.  @iofbonehealth

The European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) is a non-profit organization, dedicated to a close interaction between clinical scientists dealing with rheumatic disorders, pharmaceutical industry developing new compounds in this field, regulators responsible for the registration of such drugs and health policy makers, to integrate the management of osteoporosis and osteoarthritis within the comprehensive perspective of health resources utilization. The objective of ESCEO is to provide practitioners with the latest clinical and economic information, allowing them to organize their daily practice, in an evidence-based medicine perspective, with a cost-conscious perception.